On Jun 27, 2018 Veracyte Inc (NASDAQ:VCYT) Shorts Strengthened By 3.35%

June 27, 2018 - By Mary Bollinger

Veracyte, Inc. (NASDAQ:VCYT) Corporate Logo

During 2018 Q1 the big money sentiment decreased to 1.04. That’s change of 0.19, from 2017Q4’s 1.23. 4 investors sold all, 24 reduced holdings as Veracyte, Inc. ratio fall. 18 rose holdings while 11 funds amassed holdings. Funds hold 20.91 million shares thus 2.49% less from 2017Q4’s 21.45 million shares.
Bankshares Of America De owns 55,158 shs for 0% of their capital. Prelude Management Lc holds 0.05% of its capital in Veracyte, Inc. (NASDAQ:VCYT) for 129,655 shs. Jpmorgan Chase holds 0% of its capital in Veracyte, Inc. (NASDAQ:VCYT) for 129,266 shs. Acuta Capital Prtn Ltd Liability holds 3.01% or 3.32M shs in its capital. Renaissance Techs Ltd Liability Com invested in 512,800 shs. Tower Research Cap Limited Liability (Trc), New York-based fund reported 4,942 shs. Geode Mgmt Ltd reported 155,288 shs. New York State Common Retirement Fund accumulated 25,200 shs or 0% of the stock. Quantum Capital Mgmt reported 0.1% in Veracyte, Inc. (NASDAQ:VCYT). Illinois-based Blair William & Il has invested 0% in Veracyte, Inc. (NASDAQ:VCYT). Royal Bank Of Canada owns 3,558 shs or 0% of their US capital. Blackrock Inc reported 1.81 million shs. Credit Suisse Ag reported 10,860 shs or 0% of all its holdings. Daiwa Group Incorporated accumulated 188 shs. Manufacturers Life Insurance Company The reported 22,338 shs.

Veracyte, Inc. had 2 insider sales and 0 buys since June 12, 2018. This’s net activity of $276,513. The insider Hall Christopher M sold 20,000 shs worth $180,464.

Veracyte Inc (NASDAQ:VCYT) had an increase of its short interest by 3.35%. It was issued in June by FINRA the 836,700 short interest on VCYT. That’s 3.35% up from 809,600 shares. Previous VCYT’s position will need 6 days to recover. It has 137,100 average volume. Veracyte Inc float short is 4.01%.

$9.29 was the last price.It’s downtrending since June 27, 2017 and is 6.02% down. VCYT underperformed the S&P500 by 18.59%.

Veracyte, Inc. operates as a molecular diagnostics firm in the United States.The firm is valued at $319.07 million. The firm uses genomic technology to resolve diagnostic ambiguity.Currently it has negative earnings. It offers Afirma Thyroid FNA Analysis solution for use in thyroid cancer diagnosis; cytopathology testing services; and the Afirma Malignancy Classifiers to manage thyroid nodule patients.

Another two news for Veracyte, Inc. (NASDAQ:VCYT) were recently released by: Globenewswire.com on June 21, 2018 with title “New Research: Key Drivers of Growth for Nicolet Bankshares, Vitamin Shoppe, Aethlon Medical, Barrett Business …”. The other Businesswire.com‘s article was titled “Veracyte Named a San Francisco Bay Area “Top Workplace” for Fifth Consecutive Year” and released on June 25, 2018.

Veracyte, Inc. (NASDAQ:VCYT) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.